Clinicians should be aware of a probable drug interaction between telithromycin and CYP2D6 substrates like nortriptyline, which can result in severe cardiac toxicity.
Answers are grounded in this paper and cite their sources.
May signal CYP2D6 interaction risk with telithromycin and nortriptyline; hypothesis-generating and should not yet change practice.
Objective To report a case of probable nortriptyline toxicity associated with a combination of telithromycin and nortriptyline. Case Summary A 50-year-old white woman was admitted to the hospital with new-onset palpitations after taking 5 days of telithromycin in combination with nortriptyline. On admission her electrocardiograph showed atrioventricular nodal reentry tachycardia. The patient was also hypotensive, with a blood pressure of 90/45 mm Hg. She had been taking nortriptyline 150 mg daily at bedtime for 10 years without complications. The final day of telithromycin therapy was completed, and nortriptyline was discontinued on admission. The tachycardia subsided with a dose of diltiazem. Discussion It is suspected that the cardiovascular symptoms observed in the patient are the result of nortriptyline toxicity caused by inhibition of CYP2D6 by telithromycin. Limited evidence shows that telithromycin may be an inhibitor of CYP2D6. An assessment of causation of the adverse effects using the Drug Interaction Probability Scale suggests a probable interaction between telithromycin and nortriptyline. Conclusion It is recommended that clinicians remain aware of possible interactions between telithromycin and known CYP2D6 substrates such as nortriptyline. Should telithromycin therapy be required, close monitoring of the potential adverse effects and/or plasma drug levels of patients taking interacting drugs is warranted.
No takes yet. Share an insight, caveat, or question.
Thomason et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: